News
There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.
Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...
Merck Manuals, a comprehensive digital health resource, announced today it has launched a new search tool enhanced by artificial intelligence to provide patients and other health care consumers with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results